New Signatera MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023 - Seite 2

Posters and Industry Session

• Jan. 19, 12:00 PM PT | Stage I-III Esophagogastric Cancers (Poster)
  Presenter: Eric Lander, M.D., Vanderbilt University
  Circulating tumor DNA as a marker of recurrence risk in locoregional esophagogastric cancers with pathologic complete response

• Jan. 19, 12:00 PM PT | Metastatic esophageal cancer (Poster)
  Presenter: Rutika Mehta, M.D., Moffitt Cancer Center
  Circulating tumor DNA (ctDNA) informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers

• Jan. 19, 12:00 pm PT | Locally advanced esophageal, gastroesophageal junctional, or gastric cancer (Poster)
  Presenter: Lei Deng, M.D., Roswell Park Comprehensive Cancer Center
  Feasibility and dynamics of preoperative circulating tumor DNA in gastroesophageal cancer patients receiving preoperative treatment

• Jan 19, 12:15 PM PT | (Industry Expert Theater)
  Presenter: Adham Jurdi, M.D., medical director of oncology, Natera, Inc.
  Applications of personalized ctDNA testing to optimize treatment decisions in patients with GI cancers
  Dr. Jurdi will discuss Natera’s growing library of clinical evidence within GI cancers as well as recent data from the ongoing CIRCULATE-Japan trial published in Nature Medicine on Jan 16th, 2023.

Additional data recently published on Anal squamous carcinoma (SCCA)

A recent study published in The Oncologist highlights Signatera’s utility in anal squamous cell carcinoma (SCCA). The paper reports results from a real-world study of 251 patients (817 plasma samples) with stage I-IV SCCA who were monitored longitudinally after completion of definitive treatment. In a subset of patients with complete clinical follow-up, ctDNA-positivity at any time after definitive treatment was associated with significantly shorter disease-free survival. Among the ctDNA-negative patients, all except one remained disease free on imaging (NPV 95.7%). Additionally, analysis of whole exome sequencing data from all 251 patients found significant genomic heterogeneity, further highlighting the value of a personalized and tumor-informed approach to ctDNA testing.

About Signatera

Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The test is available for both clinical and research use, and has been granted three Breakthrough Device Designations by the FDA for multiple cancer types and indications. The Signatera test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual’s tumor. Signatera is intended to detect and quantify cancer left in the body, at levels down to a single tumor molecule in a tube of blood, to identify recurrence earlier and to help optimize treatment decisions.